PTH and osteogenesis imperfecta: The treatment rate in this study was consistent with a recent US claims data study that combined another commercial database with state Medicaid and Medicare data, which reported treatment with bisphosphonates, denosumab, romosozumab, and PTH analogs in 23% of all OI patients.26